Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.75
NAS:AMRN's Cash-to-Debt is ranked lower than
84% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:AMRN: 0.75 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AMRN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: N/A Max: No Debt
Current: 0.75
Equity-to-Asset -0.16
NAS:AMRN's Equity-to-Asset is ranked lower than
94% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:AMRN: -0.16 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AMRN' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.11  Med: -0.1 Max: 1
Current: -0.16
-1.11
1
Piotroski F-Score: 5
Altman Z-Score: -6.11
Beneish M-Score: -2.46
WACC vs ROIC
11.99%
-801.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -43.88
NAS:AMRN's Operating Margin % is ranked higher than
58% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:AMRN: -43.88 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AMRN' s Operating Margin % Range Over the Past 10 Years
Min: -691.08  Med: -148.59 Max: -43.88
Current: -43.88
-691.08
-43.88
Net Margin % -55.70
NAS:AMRN's Net Margin % is ranked higher than
55% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:AMRN: -55.70 )
Ranked among companies with meaningful Net Margin % only.
NAS:AMRN' s Net Margin % Range Over the Past 10 Years
Min: -630.82  Med: -122.45 Max: -55.7
Current: -55.7
-630.82
-55.7
ROA % -46.34
NAS:AMRN's ROA % is ranked lower than
62% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:AMRN: -46.34 )
Ranked among companies with meaningful ROA % only.
NAS:AMRN' s ROA % Range Over the Past 10 Years
Min: -549.69  Med: -66.17 Max: -26.61
Current: -46.34
-549.69
-26.61
ROC (Joel Greenblatt) % -4398.08
NAS:AMRN's ROC (Joel Greenblatt) % is ranked lower than
80% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:AMRN: -4398.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AMRN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -231547.22  Med: -8240.48 Max: -1589.48
Current: -4398.08
-231547.22
-1589.48
3-Year Revenue Growth Rate 57.20
NAS:AMRN's 3-Year Revenue Growth Rate is ranked higher than
88% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:AMRN: 57.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AMRN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -75.7 Max: 57.2
Current: 57.2
0
57.2
3-Year EBITDA Growth Rate -30.60
NAS:AMRN's 3-Year EBITDA Growth Rate is ranked lower than
83% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:AMRN: -30.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AMRN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -31.4 Max: 66.3
Current: -30.6
0
66.3
3-Year EPS without NRI Growth Rate -31.60
NAS:AMRN's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:AMRN: -31.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AMRN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -81.1  Med: -16.2 Max: 88.5
Current: -31.6
-81.1
88.5
GuruFocus has detected 2 Warning Signs with Amarin Corp PLC $NAS:AMRN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AMRN's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AMRN Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q3 2016

AMRN Guru Trades in Q3 2016

Paul Tudor Jones 29,802 sh (New)
Jim Simons 50,600 sh (New)
» More
Q4 2016

AMRN Guru Trades in Q4 2016

Jim Simons 386,000 sh (+662.85%)
Paul Tudor Jones 10,998 sh (-63.10%)
» More
Q1 2017

AMRN Guru Trades in Q1 2017

Steven Cohen 300,000 sh (New)
Jim Simons 1,730,200 sh (+348.24%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AVDL, NAS:NVET, NAS:PRTA, NAS:ALKS, NAS:JAZZ, LSE:SHP » details
Traded in other countries:EH3A.Germany,
Headquarter Location:Ireland
Amarin Corp PLC is a biopharmaceutical company with expertise in lipid science. The Company is engaged in commercialization and development of therapeutics to improve cardiovascular health.

Amarin Corp PLC, formerly known as Ethical Holdings plc was incorporated under the laws of England and Wales on March 1, 1989 under the Companies Act 1985. It is a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. The Company's product Vascepa (icosapent ethyl) capsules is approved by the U.S. Food and Drug Administration for the use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG>500mg/dL) hypertriglyceridemia. On January 28, 2013 the Company commenced full commercial launch of Vascepa. The Company refers to its second indication for Vascepa as the ANCHOR indication. The FDA views the proposed ANCHOR indication as ostensibly and impliedly an indication to reduce cardiovascular risk. In addition, in December 2011, the Company announced commencement of patient dosing in cardiovascular outcomes study of Vascepa, titled REDUCE-IT or Reduction of Cardiovascular Events with EPA-Intervention Trial. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing cardiovascular events in a high risk patient population on statin therapy. On January 28, 2013, the Company commenced full commercial launch of Vascepa in the United States for use in the MARINE indication. The Company now markets Vascepa in the United States through sales force of approximately 150 sales professionals and also employed marketing and medical affairs personnel to support commercialization of Vascepa. As of February 1, 2014, over 16,000 clinicians had written prescriptions for Vascepa. In November 2010, the Company reported top-line data for the MARINE trial. Vascepa was well tolerated in the MARINE trial, with a safety profile comparable to placebo and there were no treatment-related serious adverse events observed. The Company uses third party manufacturers and suppliers to manufacture clinical and commercial quantities of ethyl-EPA, which constitutes the only active pharmaceutical ingredient within Vascepa, to encapsulate, bottle and package Vascepa and to maintain inventory of Vascepa. The Company currently relies on Patheon for the encapsulation of Vascepa. The Companies competitors include GlaxoSmithKline plc and AbbVie, Inc., and Niaspan. The Company is subject to regulation by government authorities, including FDA.

Top Ranked Articles about Amarin Corp PLC

Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017
Amarin Corporation plc (Nasdaq: AMRN) to Ring The Nasdaq Stock Market Opening Bell
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides
Amarin to Present at the Jefferies 2017 Global Healthcare Conference
Amarin to Report First Quarter 2017 Results and Host Conference Call on May 3, 2017
Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study

REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Reach Onset of Target Final Primary Major Adverse Cardiovascular Event Near the End of 2017

BEDMINSTER, N.J., and DUBLIN, Ireland, March 16, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the onset of approximately 80% of the target aggregate number of primary cardiovascular events within the REDUCE-IT study. This milestone has triggered preparation for a pre-specified interim efficacy and safety analysis by the study’s independent Data Monitoring Committee (DMC). Amarin currently expects the independent interim analysis to be conducted before the end of the third calendar quarter of this year.
Interim Analysis Expected in Q3 The REDUCE-IT study's event rate continues to track consistently with Amarin’s existing public guidance for the timing of the interim analysis and study completion. A pre-specified interim efficacy and safety analysis is designed to be conducted upon achieving approximately 80% of the target 1,612 aggregate primary major adverse cardiovascular events within the study. REDUCE-IT patients are in the process of completing a study visit over the coming months, after which additional time is required by the contract research organizations to finish collecting and preparing data for transfer to and analysis by the DMC. This data preparation and transfer process is expected to take several months as is typical for large-scale, multi-national studies, and consistent with the process for the first pre-specified interim analysis of the REDUCE-IT study, regardless of the strength of the study results. The DMC's analysis is anticipated to occur before the end of the third calendar quarter of 2017. Amarin will remain blinded to the interim and ongoing results of the REDUCE-IT study until after the study is ready to be stopped either at the interim analysis or at the final analysis. Guidelines for the independent DMC to recommend stopping the study for overwhelming efficacy require that the study achieve statistical significance on the primary endpoint and generate robust findings on certain, pre-specified secondary outcome measures. Given the high thresholds of overwhelming efficacy required prior to a DMC recommending an early stop to a cardiovascular outcomes trial like REDUCE-IT, Amarin continues to expect that the DMC's interim analysis will result in a recommendation to continue the REDUCE-IT study as planned to completion of 100% of the target events. The efficacy requirements detailed to the DMC for early study stoppage after the 80% interim assessment are high and include robustness thresholds for underlying data that go beyond the assessment for statistical significance on the analysis of the primary endpoint after the expected completion of the study at 100% of planned events. First Multinational Outcomes Study to Evaluate Cardiovascular Benefit of High-Dose EPA Therapy as an Add-on to Statin Therapy Heart disease remains the number one cause of death in the United States. REDUCE-IT is the first multinational outcomes study being conducted to evaluate the cardiovascular benefits of treating patients with high cardiovascular risk who, despite having their LCL-cholesterol controlled with statin therapy, have elevated triglyceride levels. The study is designed to examine whether the demonstrated clinical effects and postulated pleiotropic cardioprotective benefits of high-dose EPA-only Vascepa therapy, when added to statin therapy, will offer improved cardiovascular outcomes for patients. The results of this important trial, if successful, could lead to improved medical care for tens of millions of patients.   The design of the REDUCE-IT cardiovascular outcomes study was published in March 2017 in Clinical Cardiology. A copy of this publication is available at: http://onlinelibrary.wiley.com/doi/10.1002/clc.22692/full. Amarin believes that the REDUCE-IT study is designed for success based on extensive review of data from clinical, epidemiologic and genetic studies. Amarin estimates that results of the trial will become available to Amarin and be publicly communicated in mid-2018. This estimated timing reflects our assumptions of the time necessary to collect vital data from all patients in the study, compile the results, and subject the results to scrutiny of the independent review committees and the REDUCE-IT operational team after reaching the onset of the target final aggregate cardiovascular event in this study. The onset of the target final aggregate cardiovascular event in this study is estimated to occur near the end of 2017. The primary endpoint of this global, double-blind study is the time to the first occurrence of a composite of major adverse cardiovascular events (MACE). Results will be compared between the Vascepa and placebo groups. The study is being conducted under a special protocol assessment (SPA) agreement with the FDA. About Amarin Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.  Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to an ongoing outcomes study.  Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a highly-pure, omega-3 fatty acid product available by prescription.  For more information about Vascepa visit www.vascepa.com.  For more information about Amarin visit www.amarincorp.com. About VASCEPA® (icosapent ethyl) capsules VASCEPA® (icosapent ethyl) capsules are a single-molecule prescription product consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. VASCEPA is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. VASCEPA is known in scientific literature as AMR101. FDA-approved Indication and Usage VASCEPA (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.The effect of VASCEPA on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. Important Safety Information for VASCEPA VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.Use with caution in patients with known hypersensitivity to fish and/or shellfish.The most common reported adverse reaction (incidence >2% and greater than placebo) was arthralgia (2.3% for VASCEPA, 1.0% for placebo). There was no reported adverse reaction >3% and greater than placebo.Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA.Adverse events and product complaints may be reported by calling 1‑855‑VASCEPA or the FDA at 1‑800‑FDA‑1088. FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM. VASCEPA has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. VASCEPA is under various stages of development for potential use in other indications that have not been approved by the FDA. Nothing in this press release should be construed as promoting the use of VASCEPA in any indication that has not been approved by the FDA. Forward-looking statements This press release contains forward-looking statements, including expectations for continued event rates, interim data review, results and related timing and announcements with respect to Amarin's REDUCE-IT cardiovascular outcomes study; expectations related to the interim and final outcomes of the REDUCE-IT study and the anticipated successful completion of the REDUCE-IT study; and statements regarding the potential and therapeutic benefits of Vascepa. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, as disclosed in filings with the U.S. Securities and Exchange Commission, Amarin's ability to effectively develop and commercialize Vascepa will depend in part on its ability to continue to effectively finance its business, efforts of third parties, its ability to create market demand for Vascepa through education, marketing and sales activities, to achieve increased market acceptance of Vascepa, to receive adequate levels of reimbursement from third-party payers, to develop and maintain a consistent source of commercial supply at a competitive price, to comply with legal and regulatory requirements in connection with the sale and promotion of Vascepa and to maintain patent protection for Vascepa. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that historical REDUCE-IT event rates may not be predictive of future results and related cost may increase beyond expectations; the risk that regulatory reviews may impact the current design of the REDUCE-IT study or cause a change in strategic direction with respect to continuation of the study; the risk that future legal determinations and interactions with regulatory authorities may impact Vascepa marketing and sales rights and efforts; the risk that Vascepa may not show clinically meaningful effects in REDUCE-IT or support regulatory approvals for cardiovascular risk reduction; and the risk that patents may not be upheld in anticipated patent litigation. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Availability of other information about Amarin Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin contact information:

Investor Relations:

Elisabeth Schwartz
Investor Relations and Corporate Communications
Amarin Corporation plc
In U.S.: 1 (908) 719-1315
[email protected]

Lee M. Stern
Trout Group
In U.S.: 1 (646) 378-2992
[email protected]

Media Inquiries:

Kristie Kuhl
Finn Partners
In U.S.: 1 (212) 583-2791
[email protected]

Read more...
Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology
BEDMINSTER, N.J. and DUBLIN, Ireland, March 15, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced the publication today of the rationale and design for the company’s REDUCE-IT Phase 3 cardiovascular outcomes study in Clinical Cardiology, available at: http://onlinelibrary.wiley.com/doi/10.1002/clc.22692/full.
Deepak L. Bhatt, M.D., M.P.H., executive director of the Interventional Cardiovascular Programs at Brigham and Women’s Hospital, professor of medicine, Harvard Medical School in Boston, Mass., is the lead author of the published article titled, “Rationale and Design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial.”REDUCE-IT is a landmark global study of approximately 8,000 patients to evaluate whether treatment with prescription pure EPA Vascepa® (icosapent ethyl) at four grams per day reduces cardiovascular events in patients, who despite having their LDL-cholesterol (LDL-C) controlled with statin therapy, have elevated triglyceride levels and demonstrate other risk factors, such as diabetes and previous cardiovascular events.“Controlling LDL-C is critically important but only one aspect of overall good cardiovascular health,” said Dr. Bhatt. “The risk of cardiovascular events remains high due to independent factors that cannot be addressed only by reducing LDL-C. The question of how best to achieve cardiovascular risk reduction beyond the benefits realized from effective management of LDL-C remains unanswered. The REDUCE-IT trial is designed to address whether the demonstrated clinical effects and postulated pleiotropic cardioprotective benefits of icosapent ethyl when added to statin therapy will offer improved cardiovascular outcomes for patients and provide physicians with a new treatment option in the studied high cardiovascular risk population.”The publication notes that, while clinical and epidemiological studies have demonstrated patients with elevated triglycerides remain at high cardiovascular risk despite controlling LDL-C, to date no study has prospectively examined this population. For this population, high dose prescription pure EPA may prove beneficial. EPA has been shown to improve relevant lipid, lipoprotein and inflammatory parameters without raising LDL-C and may have pleiotropic benefits. An open label, blinded endpoint outcomes study in Japan of low doses of prescription pure EPA added to statin therapies has been shown to produce further cardiovascular event reduction with moderately elevated triglycerides, by 19% in the overall population and by 53% in a subgroup of patients similar to those enrolled in the REDUCE-IT study. REDUCE-IT is evaluating whether treatment with high dose EPA reduces ischemic events in statin-treated patients with persistent elevated triglycerides.    â€œDespite significant advances in the diagnosis, management, and understanding of cardiovascular disease, it remains the leading killer in this country,” said Steven B. Ketchum, Ph.D., president of R&D and chief scientific officer of Amarin. “We are confident that REDUCE-IT will provide important answers on whether the addition of prescription pure EPA Vascepa to patients with persistent elevated triglycerides after statin therapy confers a meaningful reduction in the occurrence of major cardiovascular events in this high-risk patient population.”Residual Cardiovascular Risk in Statin-Treated PatientsCardiovascular disease remains the leading cause of death in the United States, with the estimated costs of treating heart attacks, strokes and other cardiovascular diseases exceeding $300 billion annually.  In the United States, more than 35 million patients are treated with statins for the primary and secondary prevention of atherosclerotic cardiovascular events, including myocardial infarctions (heart attacks), and stroke.  Despite the demonstrated clinical benefits of lowering LDL-C with statins, significant residual cardiovascular risk remains for statin-treated patients. Vascepa is being studied in REDUCE-IT as an add-on to statin therapy to further reduce cardiovascular risk, not as a replacement for statin therapy. About REDUCE-IT REDUCE-IT is a global Phase 3, randomized, multicenter, double-blind, placebo-controlled study designed to evaluate whether treatment with Vascepa reduces cardiovascular events in patients who despite stabilized statin therapy have elevated triglyceride levels and other cardiovascular risk factors. The primary endpoint of the study is the time to the first occurrence of the composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina. Secondary endpoints include time to event analyses of components of the primary endpoint.  The study is being conducted under a special protocol assessment agreement with the FDA.Additional information on the REDUCE-IT trial and Amarin's other clinical studies of Vascepa can be found at www.clinicaltrials.gov.About Vascepa® (icosapent ethyl) capsulesVascepa® (icosapent ethyl) capsules are a single-molecule prescription product consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. Vascepa is known in scientific literature as AMR101.FDA-approved Indication and UsageVascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe ( ≥ 500 mg/dL) hypertriglyceridemia.The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.Important Safety Information for VascepaVascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components.Use with caution in patients with known hypersensitivity to fish and/or shellfish.The most common reported adverse reaction (incidence > 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo). There was no reported adverse reaction > 3% and greater than placebo.Patients receiving treatment with Vascepa and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.Patients should be advised to swallow Vascepa capsules whole; not to break open, crush, dissolve, or chew Vascepa.Adverse events and product complaints may be reported by calling 1‑855‑VASCEPA or the FDA at 1‑800‑FDA‑1088.FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.Vascepa has been approved for use by the United States Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride levels in adult patients with severe ( ≥ 500 mg/dL) hypertriglyceridemia. Vascepa is under various stages of development for potential use in other indications that have not been approved by the FDA. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA.About AmarinAmarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to the ongoing REDUCE-IT cardiovascular outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa, visit www.vascepa.com. For more information about Amarin, visit www.amarincorp.com.Forward-looking statements This press release contains forward-looking statements such as expectations regarding the ability of REDUCE-IT to provide important answers on whether the addition of Vascepa to statin therapy would confer a meaningful reduction in the occurrence of major cardiovascular events in the patient population studied. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties.  For example, statements related to the potential efficacy and therapeutic benefits of Vascepa have been subject to different interpretations on matters such as the potential clinical importance of lowering triglyceride levels in studied patients. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with complex clinical trials like REDUCE-IT and research and development and clinical trial risk generally; differing views on interpretation of clinical trial results including the results of the cited Japanese study and other relevant studies; and reliance on third parties. Due to these risks and other uncertainties, REDUCE-IT may not generate positive or useful results. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.Availability of other information about AmarinInvestors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information:

Investor Relations:
Elisabeth Schwartz
Amarin Corporation plc
In U.S.: 1 (908) 719-1315
[email protected]

Lee M. Stern
Trout Group
In U.S.: 1 (646) 378-2922
[email protected]

Media Inquiries:
Ovidio Torres
Finn Partners
In U.S.: 1 (312) 329 3911
[email protected]

Read more...

Ratios

vs
industry
vs
history
PS Ratio 6.71
AMRN's PS Ratio is ranked higher than
64% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. AMRN: 6.71 )
Ranked among companies with meaningful PS Ratio only.
AMRN' s PS Ratio Range Over the Past 10 Years
Min: 2.82  Med: 33 Max: 600
Current: 6.71
2.82
600
EV-to-EBIT -22.69
AMRN's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AMRN: -22.69 )
Ranked among companies with meaningful EV-to-EBIT only.
AMRN' s EV-to-EBIT Range Over the Past 10 Years
Min: -54.7  Med: -2.7 Max: 0.4
Current: -22.69
-54.7
0.4
EV-to-EBITDA -23.03
AMRN's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AMRN: -23.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMRN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -61.5  Med: -2.8 Max: 0.4
Current: -23.03
-61.5
0.4
Current Ratio 1.99
AMRN's Current Ratio is ranked lower than
75% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AMRN: 1.99 )
Ranked among companies with meaningful Current Ratio only.
AMRN' s Current Ratio Range Over the Past 10 Years
Min: 0.27  Med: 3.68 Max: 35.14
Current: 1.99
0.27
35.14
Quick Ratio 1.68
AMRN's Quick Ratio is ranked lower than
75% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AMRN: 1.68 )
Ranked among companies with meaningful Quick Ratio only.
AMRN' s Quick Ratio Range Over the Past 10 Years
Min: 0.22  Med: 3.66 Max: 35.14
Current: 1.68
0.22
35.14
Days Inventory 216.57
AMRN's Days Inventory is ranked lower than
74% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. AMRN: 216.57 )
Ranked among companies with meaningful Days Inventory only.
AMRN' s Days Inventory Range Over the Past 10 Years
Min: 209.74  Med: 262.76 Max: 650.68
Current: 216.57
209.74
650.68
Days Sales Outstanding 77.23
AMRN's Days Sales Outstanding is ranked lower than
56% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. AMRN: 77.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMRN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.49  Med: 54.45 Max: 77.23
Current: 77.23
50.49
77.23
Days Payable 154.71
AMRN's Days Payable is ranked higher than
78% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. AMRN: 154.71 )
Ranked among companies with meaningful Days Payable only.
AMRN' s Days Payable Range Over the Past 10 Years
Min: 64.39  Med: 146.87 Max: 195.34
Current: 154.71
64.39
195.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.00
AMRN's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AMRN: -16.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMRN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -271.2  Med: -38.1 Max: 21.2
Current: -16
-271.2
21.2

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.20
AMRN's Price-to-Median-PS-Value is ranked higher than
92% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. AMRN: 0.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMRN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.12 Max: 14.82
Current: 0.2
0.01
14.82
Earnings Yield (Greenblatt) % -4.41
AMRN's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AMRN: -4.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMRN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -16961.9  Med: -19.1 Max: 7646.9
Current: -4.41
-16961.9
7646.9

More Statistics

Revenue (TTM) (Mil) $139.18
EPS (TTM) $ -0.33
Beta1.90
Short Percentage of Float0.00%
52-Week Range $2.19 - 4.47
Shares Outstanding (Mil)272.29 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 165 385 531
EPS ($) -0.21 0.10 0.56
EPS without NRI ($) -0.21 0.10 0.56
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:AMRN

Headlines

Articles On GuruFocus.com
Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017 Jul 26 2017 
Amarin Corporation plc (Nasdaq: AMRN) to Ring The Nasdaq Stock Market Opening Bell Jun 12 2017 
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in Stati Jun 12 2017 
Amarin to Present at the Jefferies 2017 Global Healthcare Conference Jun 01 2017 
Amarin to Report First Quarter 2017 Results and Host Conference Call on May 3, 2017 Apr 25 2017 
Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Advers Mar 16 2017 
Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clin Mar 15 2017 
Amarin Appoints Michael W. Kalb Chief Financial Officer Jun 30 2016 
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Paramete Jun 11 2016 
Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Jun 06 2016 

More From Other Websites
Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017 Jul 26 2017
Here's Why Amarin Corporation plc Surged 34% Higher in June Jul 10 2017
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock? Jun 28 2017
Today's Research Reports on Stocks to Watch: OraSure Technologies and Amarin Corporation Jun 28 2017
ETFs with exposure to Amarin Corp. Plc : June 27, 2017 Jun 27 2017
Cantor Pounds The Table On Amarin Corporation plc (ADR) (AMRN) Jun 26 2017
3 Cheap Healthcare Stocks You Can Buy Right Now Jun 26 2017
Opening Bell, June 13, 2017 Jun 13 2017
Today's Bell Ringer, June 13, 2017 Jun 13 2017
Amarin Corporation plc (Nasdaq: AMRN) to Ring The Nasdaq Stock Market Opening Bell Jun 12 2017
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in... Jun 12 2017
Amarin to Present at the Jefferies 2017 Global Healthcare Conference Jun 01 2017
3 Healthcare Stocks for Savvy Investors May 24 2017
ETFs with exposure to Amarin Corp. Plc : May 22, 2017 May 22 2017
Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care May 18 2017
Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 May 10 2017
Is the Options Market Predicting a Spike in Amarin Corporation (AMRN) Stock? May 08 2017
Edited Transcript of AMRN earnings conference call or presentation 3-May-17 12:00pm GMT May 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}